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Objective: The attempt to block one type of receptor tyrosine kinase (RTK) signaling has been considered
a main strategy for cancer therapy; however, cancer cells may survive using alternative RTK signaling.
Thus, targeting multiple RTKs simultaneously may be a better treatment strategy. Previously, we
demonstrated that brain-derived neurotrophic factor (BDNF) via activating tropomyosin receptor kinase
B (TrkB) is a survival factor for transitional cell carcinoma (TCC). Others have reported that autocrine
vascular endothelial growth factor (VEGF) pathways also play a crucial role in TCC growth. We aim to
examine the in vitro and in vivo effects of BDNF plus VEGF on the TCC cell line BFTC905 derived from the
bladder cancer of a Taiwanese patient with black foot disease.
Materials and Methods: Cell numbers were counted after administration of 50 nM BDNF and/or VEGF to
the BFTC905 or primary human urothelial cell (HUC) cultures for 96 hours. The volumes of the xenograft
tumors were measured 6 weeks after weekly injections of 100 ng BDNF and/or VEGF into the cancer cell-
loading site of NOD.CB17-Prkdcscid/Tcu mice. The expression of TrkB in HUCs and VEGF receptor FLT-1 in
BFTC905 cells and HUCs, as well as CD34 and Ki-67 in the xenograft tumors was determined by Western
blotting.
Results: The effects of increasing BFTC905 cell numbers were as follows: BDNF þ VEGF >
BDNF > VEGF > control after 96 hours of treatment. The VEGF receptor FLT-1 was expressed in BFTC905
cells. Exogenous BDNF and/or VEGF did not promote the proliferation of HUCs. In addition, TrkB and FLT-
1 were very weakly expressed in HUCs. After treatment for 5 weeks, the effects of exogenously
administered BDNF and/or VEGF on the xenograft tumor volume were as follows:
BDNF þ VEGF > BDNF > VEGF > control. However, similar tumor sizes with few metastases were found
in the four groups of mice after treatment for 6 weeks. The expression levels of the angiogenic marker
CD34 and proliferative marker Ki-67 were also similar among these four groups of xenograft tumors.
Conclusion: Exogenous BDNF plus VEGF additively promotes the early growth of BFTC905 in vitro and
in vivo without affecting the normal urothelium. Targeted blockade of both TrkB and VEGF signaling
might be an effective treatment for adjuvant bladder cancer therapy or in the early stage of high-grade
TCC.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.it, Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
uang).
ddhist Compassion Relief Tzu Chi1. Introduction
Urinary bladder cancer is the ninthmost commonmalignancy in
the world [1]. Pathologically, more than 90% of bladder cancers are
transitional cell carcinoma (TCC) [2,3]. Once metastasis involves
distal organs, the median survival is approximately 1 year despiteFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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should be explored.
The products of tyrosine kinase genes regulate cellular func-
tions, including proliferation, differentiation, and motility [5].
Several receptor tyrosine kinases (RTKs) overexpressed in cancer
tissues have been conﬁrmed to be oncogenes [6]. Overexpression of
some growth factors and their corresponding RTKs reported in
bladder cancer, such as epidermal growth factor receptor and
platelet-derived growth factor receptor b, has been found to be
associated with poor clinical outcomes [7]. However, there have
been only a few clinical trials of target therapy for bladder cancer
because some preclinical trials for certain RTKs showed disap-
pointing results [7]. Unfortunately, resistance from multiple
mechanisms has been reported in target therapy using one drug to
block a speciﬁc RTK [6]. In addition, results from microarray and
high-density oligonucleotide array showed that cancer cells can
survive through several RTK signal pathways [8,9]. Therefore, the
strategy for future cancer therapy is to ﬁnd a drug that blocks
multiple targets or combinations of drugs to block multiple RTKs
[10,11].
In our previous reports, brain-derived neurotrophic factor
(BDNF) and tropomyosin receptor kinase B (TrkB) were found in
three TCC cell lines (BFTC905, TSGH8301, and T24) [12]. In human
TCC specimens, increased immunostaining for BDNF and TrkB was
observed compared with that in normal tissues [13]. The prolifer-
ation and invasiveness of BFTC905 cells were enhanced by BDNF
[12]. TrkB antibody suppressed proliferation, elicited cytotoxicity,
and inhibited migration [14]. These results indicate that both BDNF
and TrkB play important roles in the progression of TCC. Vascular
endothelial growth factor (VEGF) receptors were overexpressed in
TCCs and bladder tumor specimens [15,16]. The autocrine VEGF
pathway was also involved in the survival and proliferation of TCCs
[15]. In this study, we demonstrated that BDNF plus VEGF additively
promoted the early growth of the Taiwan TCC cell line BFTC905
in vitro and in vivo. In the future, targeted blockade of both VEGF
receptor (VEGFR) and TrkB signaling may be an effective adjuvant
postoperative bladder cancer therapy or treatment in the early
stage of high- grade TCC when patients refuse surgery.
2. Materials and methods
2.1. Cell line and cell culture
TCC cell line BFTC905 with a pathologic grade of three was
purchased from the Bioresource Collection and Research Center
(Hsinchu, Taiwan). BFTC905 is derived from a patient in Taiwan
with black foot disease [16]. These cells were maintained in RPMI
1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 mg/mL
streptomycin, L-glutamine (0.03%), and sodium bicarbonate (2.2%).
Primary human urothelial cells (HUCs) were also used in this
investigation (ScienCell Research Laboratories, Carlsbad, CA, USA),
and maintained in a special culture medium (No. 4312, ScienCell
Research Laboratories). Both BFTC905 cells and HUCs were cultured
in 5% CO2 at 37C in a humidiﬁed incubator.
2.2. Cell proliferation assay
The growth of 1  104 BFTC905 cells or 5  103 HUCs was
determined in a 10-cm dish containing RPMI medium supple-
mented with 1% FBS or a special medium, respectively, plus 50 nM
recombinant human BDNF (PeproTech, Rocky Hill, NJ, USA), or
50 nM recombinant human VEGF (PeproTech) or both. Adminis-
tration of an equal volume of phosphate buffered saline (PBS) was
used as a control. Subsequently, the cells were recultured withBDNF, VEGF, or both on hour 48. Cell counts were calculated using a
hemocytometer 48 hours and 96 hours after incubation.2.3. Mouse xenograft model
NOD.CB17-Prkdcscid/Tcu male mice, 3w4 weeks old, weighing
approximately 20 g and raised by the Laboratory Animal Center of
Tzu Chi University were chosen for the study. Mice were housed in
isolation cages with autoclaved bedding in a speciﬁc pathogen-free
room with 12-hour light-dark cycles. Sterile water and food were
supplied by the staff of the Laboratory Animal Center of Tzu Chi
University.
1.0  106 BFTC905 cells suspended in 500 mL PBS were
implanted subcutaneously into the right inguinal area of the mice.
Tumor dimensions were measured weekly and the tumor volumes
were calculated using the formula: [1/2]  a  b2, where a and b
represent the largest and smallest tumor diameters, respectively
[17]. Body weight was also measured weekly. One hundred ng of
recombinant human BDNF, VEGF, or both in 50 mL distilled water
was injected subcutaneously into the loading site of cancer cells
weekly, starting the day following tumor injection. Drug treatment
lasted for 5 weeks. In the control group, 50 mL distilled water was
administered into the same location. After 6 weeks, mice were
sacriﬁced using a carbon dioxide asphyxiator, and a necropsy was
performed immediately. The livers and lungs were also checked for
possible metastases.2.4. Western blot analysis
Cells were homogenized in ice-cold cell extract buffer, pH 7.6,
containing 0.5 mM dithiothreitol, 0.2 mM EDTA, 20 mM hydrox-
yethyl piperazineethanesulfonic acid (HEPES), 2.5 mM MgCl2,
75 mM NaCl, 0.1 mM Na3VO4, 50 mM NaF, and 0.1% Triton X-100.
Protease inhibitors, including 1 mg/mL aprotinin, 0.5 mg/mL leu-
peptin, and 100 mg/mL 4-(2-aminoethyl)-benzenesulfonyl ﬂuoride
(AEBSF), were added to the cell suspension. Xenograft tumors were
homogenized with the same buffer solution as the cell culture
except 1% Triton X-100 was used, followed by the addition of a
complete protease inhibitor cocktail tablet (Roche Applied Science,
Indianapolis, IN, USA). The protein concentrations were determined
by a protein assay kit (Bio-Rad, Hercules, CA, USA). Sodium dodecyl
sulfate polyacrylamide gel electrophoresis was performed as pre-
viously described [12]. All antibodies were obtained from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA), including anti-TrkB
(sc-8316), anti-VEGF receptor FLT-1 (sc-31173), anti-Ki-67 (sc-
15402), and anti-CD34 (sc-9095). Expression of a-tubulin (anti-a-
tubulin, sc-8305) or ERK2 (anti-ERK2, sc-154) was used as the in-
ternal standard. The intensity of immunoreactive proteins was
calculated by National Institutes of Health software ImageJ V.1.40.
The intensity ratio was calculated by dividing the intensity of Ki-67
or CD34 by that of a-tubulin.2.5. Statistical analysis
Data were expressed as mean  standard error of mean (SEM)
and evaluated by one-way analysis of variance (ANOVA) to compare
the in vitro and in vivo growth difference at each time point among
the four groups of animals (i.e., controls, and treatment groupswith
BDNF, VEGF, and BDNF þ VEGF). Posttests with Bonferroni multiple
comparison test after repeated measures one-way ANOVA were
used. In all tests, p < 0.05 was considered statistically signiﬁcant
and labeled by an asterisk on the ﬁgures. No signiﬁcant change was
labeled “n.s.” (not signiﬁcant).
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3.1. BDNF plus VEGF exerted the largest effect on the increase of
BFTC905 cell numbers in vitro
As shown in Fig. 1A, administration of 50 nM BDNF, 50 nM VEGF
or both for 48 hours did not increase the numbers of BFTC905 cells
compared with the controls (n ¼ 3; p ¼ 0.27, one-way ANOVA).
However, treatment for 96 hours signiﬁcantly increased their
numbers (n ¼ 3; p < 0.0001, one-way ANOVA). The order of the
effect at 96 hours following drug administration was
BDNF þ VEGF > BDNF > VEGF > controls. However, the difference
in cell counts between BDNF and VEGF treatment, and between
control and VEGF treatment, did not reach statistical signiﬁcance.
The number of cells in the presence of BDNF plus VEGF was
(1.75  0.38)  105, which was approximately the number of cells
combined under BDNF [(9.23  0.5)  104] and VEGF
[(7.70  0.27)  104] treatment. Expression of TrkB was conﬁrmed
in our previous report [12], and FLT-1, a VEGFR, was also expressed
in BFTC905 cells (Fig. 1B).Fig. 2. Effects of exogenous brain-derived neurotrophic factor (BDNF) and/or vascular
endothelial growth factor (VEGF) on human urothelial cells (HUCs) in vitro. (A) HUCs
were treated with 50 nM BDNF and/or VEGF at 0 and 48 hours. Cell proliferation was
measured during a 96-hour incubation. Values are mean  standard error of the mean
from three separate experiments. (B) Very weak expression of FLT-1 and TrkB in HUCs is
detected on Western blotting. ERK2 ¼ extracellular regulated kinase; FLT-1 ¼ vascular
endothelial growth factor receptor 1; TrkB ¼ tropomyosin receptor kinase B.3.2. BDNF and/or VEGF had no effect on the proliferation of HUC
cells in vitro
Growth factors that promote the proliferation of TCC cells
without affecting the proliferation of normal urothelium would be
considered the best candidates for therapy in targeted blockade. A
slower proliferation rate was observed for HUC cells (from 5  103
to 1.5104) compared with the rapid proliferation of BFTC905 cells
in control medium (from 1104 to 6.14105) in 96 hours. The HUC
cell counts among control, BDNF, VEGF, and BDNF plus VEGF
treated groups were not statistically different until 96 hours afterFig. 1. (A) Effects of exogenous brain-derived neurotrophic factor (BDNF) and/or
vascular endothelial growth factor (VEGF) on BFTC905 cells in vitro. BFTC905 cells
cultured in undernourished medium (1% fetal bovine serum) were treated with 50 nM
BDNF and/or VEGF at 0 and 48 hours. Cell proliferation was measured during a 96-hour
incubation. Values are mean  standard error of the mean from three separate ex-
periments. * p< 0.05. (B) Expression of FLT-1 in BFTC905 cells detected by Western
blotting. ERK2 ¼ extracellular regulated kinase; FLT-1 ¼ vascular endothelial growth
factor receptor 1.administration (Fig. 2A). Furthermore, we found that TrkB and FLT-
1 were very weakly expressed in HUC cells on Western blotting
(Fig. 2B).
3.3. BDNF plus VEGF exhibited the largest growth effect on BFTC905
xenograft tumors in vivo following 35 days of treatment
BDNF, VEGF, and BDNF plus VEGF administered weekly at the
tumor loading sites in the mice all promoted xenograft tumorFig. 3. Exogenous 100-ng brain-derived neurotrophic factor (BDNF) and/or 100-ng
vascular endothelial growth factor (VEG) in 50 mL distilled water was injected sub-
cutaneously into the loading site of BFTC905 cells (1 106 BFTC905 cells) once a week,
starting the day following tumor injection. The xenograft tumor volume in severe
combined immunodeﬁciency mice was measured weekly for 5 weeks. * p< 0.05.
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BDNF plus VEGF, whereas VEGF exerted the smallest effect.
Compared with vehicle injection, BDNF plus VEGF exhibited a
signiﬁcant increase in tumor volume at 21 days after drug
treatment, and this drug combination continued to promote the
largest tumor growth. Signiﬁcant growth promotion was
observed for BDNF at 35 days after treatment. At the end of
the 35-day treatment, mean tumor volumes were
615.2  104.0 mm3, 492.7  68.6 mm3, 391.5  127.9 mm3, and
153.2  40.2 mm3 in the BDNF þ VEGF, BDNF, VEGF, and control
groups, respectively.Fig. 4. Volumes and markers for xenograft tumors in severe combined immunodeﬁciency
treatment. (B) Expression of CD34 after exogenous brain-derived neurotrophic factor (BDNF)
are mean  standard error of the mean (SEM) from three separate experiments. (C) Expressio
mean  SEM from three separate experiments. B þ V ¼ BDNF þ VEGF; n.s. ¼ no signiﬁcan3.4. No signiﬁcant difference in tumor volumes or expression of
CD34 and Ki-67 in BFTC905 xenografts 6 weeks after BDNF and/or
VEGF administration
After the 6-week treatment, the volumes of BFTC905 xenografts
reached a mean 739.2  172.0 mm3, 574.3  89.1 mm3,
416.2  99.5 mm3, and 703.0  230.0 mm3 in the BDNF þ VEGF,
BDNF, VEGF, and control groups, respectively (Fig. 4A). Following
one-way ANOVA and post-tests with Bonferroni multiple compar-
isons, no signiﬁcant difference in tumor volumes was observed
among the four groups. One small (1mm in diameter) gross hepaticmice. (A) Xenograft tumor volume measured from mice sacriﬁced after 6 weeks of
and/or vascular endothelial growth factor (VEGF) in BFTC905 xenograft tumors. Values
n of Ki-67 after exogenous BDNF and/or VEGF in BFTC905 xenograft tumors. Values are
ce.
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mouse in the VEGF group showedmultiple small metastases (1 mm
in diameter) over the right lung. Peritoneal seeding was also
observed in the two previously mentioned mice in the VEGF group,
and one mouse each in the BDNF and VEGF plus BDNF group. No
gross metastases were found in the control group.
VEGF has been demonstrated to promote angiogenesis, such as
in bladder cancer [18]. In addition, Nakamura et al reported that
BDNF induces VEGF expression in neuroblastoma cells [19]. We
therefore examined whether the angiogenic effect affected the
growth of xenograft tumors after BDNF and/or VEGF administra-
tion. CD34 is a marker for angiogenesis in bladder cancer [20] and
Ki-67 is a nuclear protein tightly associated with cell proliferation
[21]. We found that the expression levels of CD34 and Ki-67 in
xenograft tumors were similar among the four experimental
groups after the 6-week treatment (Fig. 4B and C).
4. Discussion
In this study, we demonstrated the promoting and additive ef-
fect of BDNF plus VEGF on the early growth of the bladder cancer
cell line BFTC905 in both a culture system and xenograft tumors.
These results suggest that BDNF and VEGF may promote TCC
growth through different signaling pathways. Of course, the pos-
sibility that both BDNF and VEGF may act on the same pathway
cannot be excluded because the dose-response effect of BDNF and
VEGF was not established in this study.
BNDF and VEGF did not promote proliferation of primary human
urothelial cells as shown by weak immunostaining of their speciﬁc
receptors TrkB and FLT-1, respectively. This is consistent with our
previous report that TrkB is weakly expressed in specimens of
normal human urothelium [13]. VEGFR has also been found in
specimens of normal human urothelium, and upregulated in
inﬂamed normal rodent urothelial cells [22]. However, no study has
investigated the proliferative effects of BDNF and/or VEGF on
normal human urothelium. Our preliminary data indicated that
BNDF and VEGF did not promote proliferation of primary human
urothelial cells.
For the past 20 years, xenograft tumors of human cancer cells
implanted subcutaneously into immunosuppressed mice have
been widely applied preclinically to evaluate the effect of anti-
cancer drugs. In our previous study, we demonstrated that fewer
cells were needed to establish xenograft tumors when the Taiwan
TCC cell line BFTC905 was used compared with T24, which is
commonly used in bladder cancer research, and another Taiwan
TCC cell line, TSGH8301 [12]. After implantation of BFTC905 cells
for 6 weeks, somemetastases were found. This ﬁnding is consistent
with a previous report that the limitations of a xenograft model are
slow growth and fewmetastases [23]. Therefore, orthotopic models
may be more appropriate for the investigation of tumor progres-
sion [24].
After 5 weeks of treatment, the growth of BFTC905 xenograft
tumors in severe combined immunodeﬁcient mice was
BDNF þ VEGF > BDNF > VEGF > controls. The difference was sta-
tistically signiﬁcant. These data are compatible with previous re-
ports that BDNF [12] and VEGF [15] are survival factors for TCCs.
However, no statistical difference in tumor sizes was observed 6
weeks after treatment with BDNF and/or VEGF. One possibility is
the large variation in tumor volumes found among individual ani-
mals. Thus, one limitation of this experiment was the insufﬁcient
number of animals used. In addition, metastases were noted after
sacriﬁce, so the original tumor sizes cannot simply reﬂect the de-
gree of cancer progression. Furthermore, the growth factor is just
one of 10 hallmarks of cancer growth [25]. Once neoplastic tumors
become uncontrolled growth, as in patients in the terminal stagesof cancer, cancer cells can survive and invade via multiple signaling
pathways. This may explain why no difference in BFTC905 xeno-
graft tumor sizes was observed after weekly administration of
growth factors for 6 weeks in our study.
It is reasonable that the angiogenic marker CD34 in human
bladder cancer specimens is considered a prognostic factor for early
recurrence [26]. To analyze microvascular density, immunostaining
of CD34, a speciﬁc marker of endothelial cells, is a commonmethod
of evaluation of angiogenesis [27]. We have also examined the
localization of CD34 in xenograft tumors by immunoﬂuorescence,
but few and scattered distribution of positive CD34 endothelial cells
were seen (results not shown). The ﬁeld we choose in microscopy
would inﬂuence the results for semiquantiﬁcation, so Western
blotting was used instead to detect the expression of CD34 in
xenograft tumors. Low immunostaining of CD34 on Western blot-
ting was correlated with the ﬁndings on immunoﬂuorescence, and
low CD34 expression may explain the reason for the low number of
metastases in this investigation. Thus, exogenous VEGF may act
directly on TCC cells to affect the growth of xenograft tumors, and
this in vivo result coincides with the in vitro observations.
Ki-67 protein is present during all active phases of the cell cycle
(G1, S, G2, and mitotic phase) but absent from resting cells (G0), so
Ki-67 expression in human bladder cancer tissues is signiﬁcantly
greater in high-grade tumors and associated with a signiﬁcantly
worse prognosis [28e30]. Nuclear Ki-67 is usually detected by
immunohistochemistry, and additional semiquantiﬁcation is used
to evaluate the proliferative status. We also examined the immu-
nostaining of Ki-67 in xenograft tumors; however, it was difﬁcult to
count cells because every ﬁeld chosen for microscopy among the
four experimental groups was almost invariably ﬁlled with positive
Ki-67 cells (results not shown). Thus, we used Western blotting to
detect changes in Ki-67 protein, and no signiﬁcant difference was
observed, as shown by the abundant expression of Ki-67 in the four
groups of xenograft tumors. No difference in the expression of Ki-
67 is consistent with no difference in the xenograft tumor sizes
among the four experimental groups after 6 weeks of treatment.
In conclusion, exogenous BDNF plus VEGF additively promoted
the early growth of bladder cancers in vitro and in vivo, without
affecting the normal urothelium. Targeted blockade of both TrkB
and VEGF signaling may be an effective treatment for adjuvant
postoperative bladder cancer therapy or in the early stage of high-
grade TCC when patients refuse surgery.Acknowledgments
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